Fariba Shojaee-Moradie

Dr. Fariba Shojaee-Moradie


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2006 in Diabetologia
Verified
Journal Article
Closed access
PDF file
FSFariba Shojaee-Moradie
Fariba Shojaee-Moradie
KBK. C. R. Baynes
K. C. R. Baynes
CPC. Pentecost
C. Pentecost
JBJ. D. Bell
J. D. Bell
ETElizabeth Thomas
Elizabeth Thomas
AUA. M. Umpleby
A. M. Umpleby

1 October 1994 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
DRD. L. Russell-Jones
D. L. Russell-Jones
AUA. M. Umpleby
A. M. Umpleby
THT. R. Hennessy
T. R. Hennessy
SBS. B. Bowes
S. B. Bowes
FSFariba Shojaee-Moradie
Fariba Shojaee-Moradie
PSP. H. Sonksen
P. H. Sonksen
Insulin-like growth factor I (IGF-I) is thought to mediate the anabolic action of growth hormone. A glucose and amino acid clamp technique was used to investigate the effects of a 3-h intravenous infusion of either 43.7 pmol.kg-1.min-1 (20 micrograms.kg-1.h-1) IGF-I or 3.4 pmol.kg-1.min-1 (0.5 mU.kg-1.min-1) insulin on whole body leucine turnover in five normal human volunteers. During the IGF-I infusion, IGF-I levels increased (P < 0.01; 26.6 +/- 2.8 to 88.9 +/- 14.2 nmol/l) and insulin levels fell (P < 0.05; 0.096 +/- 0.018 to 0.043 +/- 0.009 nmol/l). During the insulin infusion, insulin levels increased (P < 0.01; 0.057 +/- 0.013 to 0.340 +/- 0.099 nmol/l), and there was no change in IGF-I. There was no significant change in leucine production rate (Ra; a measure of protein degradation) during the IGF-I infusion (2.23 +/- 0.17 to 2.13 +/- 0.2 mumol.kg-1.min-1), but there was an increase (P < 0.03) in nonoxidative leucine disposal rate (Rd; a measure of protein synthesis; 1.83 +/- 0.15 to 2.05 +/- 0.21 mumol.kg-1.min-1). In contrast, insulin reduced (P < 0.02) leucine Ra (1.81 +/- 0.24 to 1.47 +/- 0.24 mumol.kg-1.min-1) and had no effect on nonoxidative leucine Rd (1.44 +/- 0.25 to 1.41 +/- 0.22 mumol.kg-1.min-1). We conclude that IGF-I, under conditions of adequate substrate supply, directly increases protein synthesis in contrast to insulin, which exerts its anabolic action by reducing proteolysis.

1 September 1996 in Journal of Mass Spectrometry
Verified
Journal Article
Closed access
FSFariba Shojaee-Moradie
Fariba Shojaee-Moradie
NJN. C. Jackson
N. C. Jackson
RJR. H. Jones
R. H. Jones
AMA. I. Mallet
A. I. Mallet
RHR. Hovorka
R. Hovorka
AUA. M. Umpleby
A. M. Umpleby

15 June 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
SSSimon Steenson
Simon Steenson
FSFariba Shojaee-Moradie
Fariba Shojaee-Moradie
MWMartin B. Whyte
Martin B. Whyte
KJKim Jackson
Kim Jackson
JLJulie A. Lovegrove
Julie A. Lovegrove
AUA. Margot Umpleby
A. Margot Umpleby
A high fructose intake exacerbates postprandial plasma triacylglycerol (TAG) concentration, an independent risk factor for cardiovascular disease, although it is unclear whether this is due to increased production or impaired clearance of triacylglycerol (TAG)-rich lipoproteins. We determined the in vivo acute effect of fructose on postprandial intestinal and hepatic lipoprotein TAG kinetics and de novo lipogenesis (DNL). Five overweight men were studied twice, 4 weeks apart. They consumed hourly mixed-nutrient drinks that were high-fructose (30% energy) or low-fructose (<2% energy) for 11 h. Oral 2H2O was administered to measure fasting and postprandial DNL. Postprandial chylomicron (CM)-TAG and very low-density lipoprotein (VLDL)-TAG kinetics were measured with an intravenous bolus of [2H5]-glycerol. CM and VLDL were separated by their apolipoprotein B content using antibodies. Plasma TAG (p < 0.005) and VLDL-TAG (p = 0.003) were greater, and CM-TAG production rate (PR, p = 0.046) and CM-TAG fractional catabolic rate (FCR, p = 0.073) lower when high-fructose was consumed, with no differences in VLDL-TAG kinetics. Insulin was lower (p = 0.005) and apoB48 (p = 0.039), apoB100 (p = 0.013) and non-esterified fatty acids (NEFA) (p = 0.013) were higher after high-fructose. Postprandial hepatic fractional DNL was higher than intestinal fractional DNL with high-fructose (p = 0.043) and low-fructose (p = 0.043). Fructose consumption had no effect on the rate of intestinal or hepatic DNL. We provide the first measurement of the rate of intestinal DNL in humans. Lower CM-TAG PR and CM-TAG FCR with high-fructose consumption suggests lower clearance of CM, rather than elevated production, may contribute to elevated plasma TAG, possibly due to lower insulin-mediated stimulation of lipoprotein lipase.

31 July 2023 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
GGGillian Leigh Garden
Gillian Leigh Garden
FSFariba Shojaee-Moradie
Fariba Shojaee-Moradie
EHEwan J. Hutchison
Ewan J. Hutchison
BFBrian Murray Frier
Brian Murray Frier
KSKenneth M. Shaw
Kenneth M. Shaw
DRDavid L. Russell-Jones
David L. Russell-Jones
Background and Aims: A preliminary study compared the use of continuous glucose monitoring (CGM) with the use of self-monitored blood glucose (SMBG) by aircraft pilots with insulin-treated diabetes in the United Kingdom, Ireland, and Austria, certified to fly commercial aircraft within the European Aviation Safety Agency ARA.MED.330 protocol. Methods: SMBG and simultaneous interstitial glucose measurements using CGM (Dexcom G6 ® ) were recorded during pre- and in-flight periods. Results: Eight male pilots (seven with type 1 diabetes and one with type 3c diabetes), median age of 48.5 years and median diabetes duration of 11.5 years, participated. The correlation coefficient ( R ) between 874 contemporaneously recorded SMBG and CGM values was 0.843, P < 0.001. The mean glucose concentration was 8.78 mmol/L (standard deviation [SD] 0.67) using SMBG compared with 8.71 mmol/L (SD 0.85) recorded using CGM. The mean absolute relative difference was 9.39% (SD 3.12). Conclusions: CGM using Dexcom G6 systems is a credible alternative to SMBG for monitoring glucose levels when insulin-treated pilots fly commercial aircraft. The study was registered with Clinical Trials.gov NCT04395378.

1 April 2013 in Journal of Hepatology
Verified
Journal Article
Open access
JCJ.F.L. Cobbold
J.F.L. Cobbold
SWS.N. Wai
S.N. Wai
JSJ. Stove
J. Stove
FSFariba Shojaee-Moradie
Fariba Shojaee-Moradie
JFJ. Fitzpatrick
J. Fitzpatrick
MTM.R. Thursz
M.R. Thursz